ImmunityBio IBRX
NASDAQ IBRX
$6.74 -0.37 (-5.13%)
At close: Nov 10, 2026 · 4:00 PM EST

ImmunityBio (IBRX) Equity Income (2021 - 2023)

Updated

ImmunityBio's Equity Income came in at -$7.55 million for FY2023, compared with -$12.11 million in FY2022.

Analysis

ImmunityBio (IBRX) Equity Income (2021 - 2023) Analysis & Trends

  • Per Business Quant, earlier years put Equity Income at -$12.11 million in FY2022 and -$803,000 in FY2021.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Equity Income (Qtr)
1 Eli Lilly 1,264.65 Bn 1,238.27 Bn 20.46 Bn -
2 Johnson & Johnson 677.74 Bn 597.60 Bn 17.30 Bn -
3 AbbVie 517.10 Bn 485.11 Bn 13.12 Bn -
4 Merck 362.23 Bn 325.17 Bn 13.19 Bn -
5 Novartis Ag 315.90 Bn 276.16 Bn 11.24 Bn -2.00 Mn
6 Astrazeneca 289.40 Bn 266.24 Bn 12.86 Bn -10.00 Mn
7 Amgen 249.90 Bn 201.56 Bn 7.58 Bn -
8 Gilead Sciences 209.15 Bn 184.26 Bn 6.73 Bn -
9 Pfizer 165.88 Bn 113.23 Bn 12.56 Bn -
10 ImmunityBio 7.48 Bn 6.24 Bn 50.94 Mn -
Historic Data

Historic Data

Download Data
DateValue
Sep 30, 2023 -1.26 Mn
Jun 30, 2023 -3.96 Mn
Mar 31, 2023 -2.34 Mn
Dec 31, 2022 -3.55 Mn
Sep 30, 2022 -4.46 Mn
Jun 30, 2022 -3.90 Mn
Mar 31, 2022 -197,000.00
Dec 31, 2021 -803,000.00
API Access

ImmunityBio Equity Income API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=equity-income&ticker=IBRX&period=max&api_key=YOUR_API_KEY